1.32

4.76% 0.06

Phio Pharmaceuticals Corp (PHIO)

Overview News Price History Financials Why PHIO Down? Discussions Forecast Stock Split

Phio Pharmaceuticals Corp stock is traded at $1.32, with a volume of 72,799. It is up +4.76% in the last 24 hours and up +23.36% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Previous Close:

$1.26

Open:

$1.27

24h Volume:

72,799

Relative Volume:

0.02

Market Cap:

$15.28M

Revenue:

Net Income/Loss:

$-8.70M

P/E Ratio:

-0.8777

EPS:

-1.5039

Net Cash Flow:

$-7.99M

1W Performance:

+11.86%

1M Performance:

+23.36%

6M Performance:

-40.81%

1Y Performance:

+1.50%

1-Day Range:

$1.27

$1.3375

1-Week Range:

$1.18

$1.3375

52-Week Range:

$0.8127

$4.1899

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name

Phio Pharmaceuticals Corp

Sector

Healthcare (1117)

Industry

Biotechnology (623)

Phone

(508) 767-3861

Address

411 SWEDELAND ROAD, KING OF PRUSSIA, MA

Employee

Twitter

@phio_pharma

Next Earnings Date

2024-11-07

Latest SEC Filings

PHIO's Discussions on Twitter

Compare PHIO vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHIO Phio Pharmaceuticals Corp	1.315	14.64M	0	-8.70M	-7.99M	-1.5039
VRTX Vertex Pharmaceuticals Inc	451.39	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	754.55	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	329.82	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	687.64	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.26	31.97B	606.42M	-1.28B	-997.58M	-6.403

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-25	Resumed	H.C. Wainwright	Buy
Aug-05-20	Initiated	H.C. Wainwright	Buy

Phio Pharmaceuticals Corp Stock (PHIO) Latest News

Mar 24, 2026

Phio Pharmaceuticals to present PH-762 cancer trial data Friday By Investing.com - Investing.com South Africa

Mar 24, 2026

Mar 23, 2026

Phio Pharmaceuticals to present PH-762 cancer trial data Friday - Investing.com

Mar 23, 2026

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement - marketscreener.com

Mar 23, 2026

A skin cancer study with 65% response sends Phio to a late-breaker stage - Stock Titan

Mar 23, 2026

Mar 21, 2026

Cancer biotech Phio Pharmaceuticals stock surges as trial shows tumor clearance at highest dose in skin cancer patients - MSN

Mar 21, 2026

Mar 20, 2026

PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill

Mar 20, 2026

Mar 17, 2026

Aug Macro: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Historical Comparison & Step-by-Step Trade Execution Guides - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Retail Trends: Is Phio Pharmaceuticals Corp being accumulated by smart money2026 Performance Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn

Mar 16, 2026

Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office - Bitget

Mar 16, 2026

Phio cancer study sees ~65% response; CEO in March 18 virtual chat - Stock Titan

Mar 16, 2026

Mar 13, 2026

Sidoti Boosts Earnings Estimates for Phio Pharmaceuticals - Defense World

Mar 13, 2026

Mar 12, 2026

PHIO: RNA therapy for skin cancer shows 85% response and no toxicities, advancing to pivotal trials - TradingView

Mar 12, 2026

Mar 11, 2026

Phio Pharmaceuticals Corp. Financial Disclosures & SEC Filings - TradingView

Mar 11, 2026

Mar 10, 2026

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT - GlobeNewswire

Mar 10, 2026

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT - TMX Newsfile

Mar 10, 2026

Cancer gene-silencing trial shows 65% response in Phio study - Stock Titan

Mar 10, 2026

Mar 07, 2026

How Phio Pharmaceuticals Corp. stock compares to industry benchmarksBuy Signal & High Accuracy Trade Signal Alerts - Naître et grandir

Mar 07, 2026

Mar 06, 2026

EV Market: Is Phio Pharmaceuticals Corp being accumulated by smart moneyJuly 2025 Sector Moves & Free Accurate Trade Setup Notifications - baoquankhu1.vn

Mar 06, 2026

Mar 05, 2026

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update - marketscreener.com

Mar 05, 2026

Cancer drug PH-762 completes safety phase as Phio raises $23.7M - Stock Titan

Mar 05, 2026

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - marketscreener.com

Mar 05, 2026

Phio cancer drug PH-762 posts 65% response; CEO hosts live Q&A - Stock Titan

Mar 05, 2026

Phio Pharmaceuticals Reports 2025 Financial Results, Extends Cash Runway into 2027 - National Today

Mar 05, 2026

Mar 04, 2026

PHIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026

Mar 03, 2026

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Sahm

Mar 03, 2026

Feb 25, 2026

PHIO Should I Buy - Intellectia AI

Feb 25, 2026

PHIO Technical Analysis & Stock Price Forecast - Intellectia AI

Feb 25, 2026

Feb 23, 2026

Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company - Weekly Voice

Feb 23, 2026

Phio Pharmaceuticals Reports Promising Phase 1b Results for Skin Cancer Therapy, Plans FDA Submission for 2026 - citybuzz -

Feb 23, 2026

Feb 21, 2026

Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 - The Courier-Journal

Feb 21, 2026

Feb 20, 2026

Is Phio Pharmaceuticals Corp. stock trending bullish2025 Major Catalysts & Advanced Technical Analysis Signals - mfd.ru

Feb 20, 2026

Feb 19, 2026

CVI and Heights disclose 9.9% Phio (PHIO) stake based on warrant holdings - Stock Titan

Feb 17, 2026

Feb 16, 2026

Will Phio Pharmaceuticals Corp. benefit from rising consumer demandWeekly Investment Report & Advanced Swing Trade Entry Alerts - mfd.ru

Feb 16, 2026

Feb 15, 2026

What are Phio Pharmaceuticals Corp.’s growth leversInsider Buying & AI Forecast for Swing Trade Picks - mfd.ru

Feb 15, 2026

DealFlow Discovery Conference: Opportunities Unveiled - timothysykes.com

Feb 15, 2026

Feb 14, 2026

Can Phio Pharmaceuticals Corp. lead its sector in growthEarnings Growth Summary & Growth Focused Stock Reports - mfd.ru

Feb 14, 2026

Feb 13, 2026